Head-To-Head Comparison: Minerva Neurosciences (NASDAQ:NERV) & Vivos Therapeutics (NASDAQ:VVOS)

Minerva Neurosciences (NASDAQ:NERV) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for Minerva Neurosciences and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1	1	1	0	2.00
Vivos Therapeutics	1	2	2	0	2.20

Minerva Neurosciences currently has a consensus price target of $10.50, indicating a potential upside of 55.56%. Vivos Therapeutics has a consensus price target of $3.42, indicating a potential upside of 243.38%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Minerva Neurosciences.

Profitability

This table compares Minerva Neurosciences and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-35.62%
Vivos Therapeutics	-98.77%	-351.28%	-87.44%

Earnings and Valuation

This table compares Minerva Neurosciences and Vivos Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42 million	($26.80)	-0.25
Vivos Therapeutics	$17.44 million	0.60	-$11.14 million	($2.07)	-0.48

Vivos Therapeutics has higher revenue and earnings than Minerva Neurosciences. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Minerva Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.93, suggesting that its stock price is 593% more volatile than the S&P 500.

Summary

Vivos Therapeutics beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.